160 related articles for article (PubMed ID: 38520423)
1. Autoimmune adverse event following COVID-19 vaccination in Seoul, South Korea.
Kim HJ; Kim MH; Park SJ; Choi MG; Chun EM
J Allergy Clin Immunol; 2024 Jun; 153(6):1711-1720. PubMed ID: 38520423
[TBL] [Abstract][Full Text] [Related]
2. Risk of vitiligo in patients with SARS-CoV-2 vaccination or infection: a nationwide cohort study.
Kim JS; Jeong CY; Lee GJ; Yeom SW; Nam KH
Eur J Dermatol; 2024 Apr; 34(2):150-157. PubMed ID: 38907545
[TBL] [Abstract][Full Text] [Related]
3. Psychiatric adverse events following COVID-19 vaccination: a population-based cohort study in Seoul, South Korea.
Kim HJ; Kim MH; Choi MG; Chun EM
Mol Psychiatry; 2024 Jun; ():. PubMed ID: 38834668
[TBL] [Abstract][Full Text] [Related]
4. Adverse events following COVID-19 vaccination in South Korea between February 28 and August 21, 2021: A nationwide observational study.
Lee DS; Kim JW; Lee KL; Jung YJ; Kang HW
Int J Infect Dis; 2022 May; 118():173-182. PubMed ID: 35276381
[TBL] [Abstract][Full Text] [Related]
5. Adverse Events in Healthcare Workers after the First Dose of ChAdOx1 nCoV-19 or BNT162b2 mRNA COVID-19 Vaccination: a Single Center Experience.
Kim SH; Wi YM; Yun SY; Ryu JS; Shin JM; Lee EH; Seo KH; Lee SH; Peck KR
J Korean Med Sci; 2021 Apr; 36(14):e107. PubMed ID: 33847085
[TBL] [Abstract][Full Text] [Related]
6. Autoimmune conditions following mRNA (BNT162b2) and inactivated (CoronaVac) COVID-19 vaccination: A descriptive cohort study among 1.1 million vaccinated people in Hong Kong.
Li X; Gao L; Tong X; Chan VKY; Chui CSL; Lai FTT; Wong CKH; Wan EYF; Chan EWY; Lau KK; Lau CS; Wong ICK
J Autoimmun; 2022 Jun; 130():102830. PubMed ID: 35461018
[TBL] [Abstract][Full Text] [Related]
7. Does autoimmune vitiligo protect against COVID-19 disease?
Post NF; Luiten RM; Wolkerstorfer A; Bekkenk MW; Böhm M
Exp Dermatol; 2021 Sep; 30(9):1254-1257. PubMed ID: 34081788
[TBL] [Abstract][Full Text] [Related]
8. COVID-19 vaccination in autoimmune diseases (COVAD) study: vaccine safety and tolerance in rheumatoid arthritis.
Naveen R; Parodis I; Joshi M; Sen P; Lindblom J; Agarwal V; Lilleker JB; Tan AL; Nune A; Shinjo SK; Salim B; Ziade N; Velikova T; Edgar Gracia-Ramos A; Saavedra MA; Day J; Makol A; Distler O; Chinoy H; Agarwal V; Aggarwal R; Gupta L; Nikiphorou E;
Rheumatology (Oxford); 2023 Jul; 62(7):2366-2376. PubMed ID: 36315075
[TBL] [Abstract][Full Text] [Related]
9. Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label and randomised phase 1 clinical trial.
Wu S; Huang J; Zhang Z; Wu J; Zhang J; Hu H; Zhu T; Zhang J; Luo L; Fan P; Wang B; Chen C; Chen Y; Song X; Wang Y; Si W; Sun T; Wang X; Hou L; Chen W
Lancet Infect Dis; 2021 Dec; 21(12):1654-1664. PubMed ID: 34324836
[TBL] [Abstract][Full Text] [Related]
10. Safety of COVID-19 Vaccination in Patients With Breast Cancer: Cross-Sectional Study in China.
Zhang S; Li J; Xu R; Chen Q; Sun G; Lin Y; Cao Y; Chen Y; Geng C; Teng Y; Nie J; Li X; Xu G; Liu X; Jin F; Fan Z; Luo T; Liu H; Wang FS; Jiang Z
JMIR Public Health Surveill; 2023 Dec; 9():e46009. PubMed ID: 38060302
[TBL] [Abstract][Full Text] [Related]
11. Autoimmune disorders reported following COVID-19 vaccination: A disproportionality analysis using the WHO database.
Kim S; Bea S; Choe SA; Choi NK; Shin JY
Eur J Clin Pharmacol; 2024 Mar; 80(3):445-453. PubMed ID: 38212538
[TBL] [Abstract][Full Text] [Related]
12. Safety of BNT162b2 mRNA COVID-19 vaccine in children with chronic kidney disease: a national population study from South Korea.
Choe YJ; Ahn YH; Gwak E; Jo E; Kim J; Choe SA
Pediatr Nephrol; 2024 Feb; 39(2):625-629. PubMed ID: 37880380
[TBL] [Abstract][Full Text] [Related]
13. Risk of autoimmune skin and connective tissue disorders after mRNA-based COVID-19 vaccination.
Ju HJ; Lee JY; Han JH; Lee JH; Bae JM; Lee S
J Am Acad Dermatol; 2023 Oct; 89(4):685-693. PubMed ID: 37187424
[TBL] [Abstract][Full Text] [Related]
14. COVID-19 vaccination-related adverse events among autoimmune disease patients: results from the COVAD study.
Sen P; Ravichandran N; Nune A; Lilleker JB; Agarwal V; Kardes S; Kim M; Day J; Milchert M; Gheita T; Salim B; Velikova T; Gracia-Ramos AE; Parodis I; Selva O'Callaghan A; Nikiphorou E; Chatterjee T; Tan AL; Cavagna L; Saavedra MA; Shinjo SK; Ziade N; Knitza J; Kuwana M; Distler O; Chinoy H; Agarwal V; Aggarwal R; Gupta L;
Rheumatology (Oxford); 2022 Dec; 62(1):65-76. PubMed ID: 35713499
[TBL] [Abstract][Full Text] [Related]
15. Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials.
Yang S; Li Y; Dai L; Wang J; He P; Li C; Fang X; Wang C; Zhao X; Huang E; Wu C; Zhong Z; Wang F; Duan X; Tian S; Wu L; Liu Y; Luo Y; Chen Z; Li F; Li J; Yu X; Ren H; Liu L; Meng S; Yan J; Hu Z; Gao L; Gao GF
Lancet Infect Dis; 2021 Aug; 21(8):1107-1119. PubMed ID: 33773111
[TBL] [Abstract][Full Text] [Related]
16. Adverse Events Following COVID-19 Vaccination in Adolescents: Insights From Pharmacovigilance Study of VigiBase.
Kim DH; Kim JH; Oh IS; Choe YJ; Choe SA; Shin JY
J Korean Med Sci; 2024 Mar; 39(8):e76. PubMed ID: 38442719
[TBL] [Abstract][Full Text] [Related]
17. High incidence of multisystem inflammatory syndrome and other autoimmune diseases after SARS-CoV-2 infection compared to COVID-19 vaccination in children and adolescents in south central Europe.
Bizjak M; Emeršič N; Zajc Avramovič M; Barbone F; Ronchese F; Della Paolera S; Conversano E; Amoroso S; Vidoni M; Vesel Tajnšek T; Mlakar G; Berce V; Markelj G; Plankar Srovin T; Golli T; Osredkar D; Koren Jeverica A; Toplak N; Pokorn M; Avšič Županc T; Ihan A; Fafangel M; Taddio A; Avčin T
Clin Exp Rheumatol; 2023 May; 41(5):1183-1191. PubMed ID: 36377567
[TBL] [Abstract][Full Text] [Related]
18. Insights into new-onset autoimmune diseases after COVID-19 vaccination.
Guo M; Liu X; Chen X; Li Q
Autoimmun Rev; 2023 Jul; 22(7):103340. PubMed ID: 37075917
[TBL] [Abstract][Full Text] [Related]
19. A Nationwide Survey of mRNA COVID-19 Vaccinee's Experiences on Adverse Events and Its Associated Factors.
Yoon D; Jeon HL; Noh Y; Choe YJ; Choe SA; Jung J; Shin JY
J Korean Med Sci; 2023 Jun; 38(22):e170. PubMed ID: 37272559
[TBL] [Abstract][Full Text] [Related]
20. COVID-19 vaccine-associated vitiligo: A cross-sectional study in a tertiary referral center and systematic review.
Tsai TF; Ng CY
J Dermatol; 2023 Aug; 50(8):982-989. PubMed ID: 37186102
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
